NLRP3 and myocardial infarction: Treatment at a dose of 150 mg every 3 months via subcutaneous injection in patients with MI attenuated the risk of recurrent cardiovascular events compared with placebo, suggesting that canakinumab potentially prevents atherosclerotic events by limiting the secretion of IL-1β by the NLRP3 inflammasome.